Gastroparesis Drugs Global Market 2024 - By Share, Growth, Demand, Trends, Forecast To 2033

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.  The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Scope Of Gastroparesis Drugs Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Gastroparesis Drugs Market Overview

Market Drivers -
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.09 billion in 2023 to $5.39 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%.  The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.  The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.

Market Trends -
Major companies operating in the gastroparesis drugs market are focusing on introducing innovative drugs, such as Gimoti (metoclopramide) nasal spray, to gain a competitive edge in the market. Gimoti (metoclopramide) nasal spray is a medication used to treat symptoms of gastroparesis in adults, improving stomach emptying by enhancing gastrointestinal motility. It bypasses the gastrointestinal tract and is absorbed directly into the bloodstream through the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity gives Evoke exclusive marketing rights for three years from the original approval date under the Hatch-Waxman Act, protecting the product from generic competition.

The gastroparesis drugs market covered in this report is segmented –
1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Get an inside scoop of the gastroparesis drugs market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Regional Insights -
North America was the largest region in the gastroparesis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies -
Major companies operating in the gastroparesis drugs market are focusing on introducing innovative drugs, such as Gimoti (metoclopramide) nasal spray, to gain a competitive edge in the market. Gimoti (metoclopramide) nasal spray is a medication used to treat symptoms of gastroparesis in adults, improving stomach emptying by enhancing gastrointestinal motility. It bypasses the gastrointestinal tract and is absorbed directly into the bloodstream through the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity gives Evoke exclusive marketing rights for three years from the original approval date under the Hatch-Waxman Act, protecting the product from generic competition.

Table of Contents
1. Executive Summary
2. Gastroparesis Drugs Market Report Structure
3. Gastroparesis Drugs Market Trends And Strategies
4. Gastroparesis Drugs Market – Macro Economic Scenario
5. Gastroparesis Drugs Market Size And Growth
…..
27. Gastroparesis Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Read Related Topics:
https://goodprnews.com/qr-code-payments-global-market-size/
https://goodprnews.com/rhamnolipids-global-market-size/
https://goodprnews.com/smart-food-labels-global-market-size/
https://topprnews.com/qr-code-payments-global-market-share/
https://topprnews.com/rhamnolipids-global-market-share/
https://topprnews.com/smart-food-labels-global-market-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model